-
Founded in:
1999-04-08 -
Country:
China -
Address:
Jilin Province Tonghua Wanwanchuan Development Zone -
Tax NO.:
91220501702337222J -
Registered Funds:
33 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ginkgo nuts (shelled) |
|
0 | ||
| NATURAL INDIGO |
|
0 | ||
| FRITILLARIAE USSURIENSIS BULBUS |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Astragali Radix |
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen.
More
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen. |
0 | ||
| Salvia Root P.E Tanshinone IIA 20% |
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen.
More
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen. |
0 | ||
| MYLABRIS |
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen.
More
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen. |
0 | ||
| lumbricus |
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen.
More
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen. |
0 | ||
| Riligustilide |
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen.
More
It can counteract the increased cerebral vascular permeability after cerebral ischemia, reduce brain water content, and alleviate brain atrophy-like changes caused by ischemia; inhibit arterial thrombosis, reduce platelet adhesion rate, inhibit ADP-induced platelet aggregation, shorten euglobulin lysis time, and reduce blood viscosity, hematocrit and fibrinogen. |
89354-45-0 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Anise oil |
|
8007-70-3 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Theophylline |
Cough and asthma medicine
More
Cough and asthma medicine |
25mg | 58-55-9 | 26 |
| Caffeine |
Cough and asthma medicine
More
Cough and asthma medicine |
15mg | 0 | |
| Theobromine |
Cough and asthma medicine
More
Cough and asthma medicine |
25mg | 83-67-0 | 9 |
| Ephedrine hydrochloride |
Cough and asthma medicine
More
Cough and asthma medicine |
10mg | 0 | |
| Belladonna Extract Powder |
Cough and asthma medicine
More
Cough and asthma medicine |
2mg | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Acetaminophen |
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects
More
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects |
250mg | 103-90-2 | 68 |
| Caffeine |
It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs.
More
It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs. |
15mg | 0 | |
| Chlorphenamine maleate |
It is an antihistamine that can relieve runny nose, nasal congestion, and sneezing symptoms.
More
It is an antihistamine that can relieve runny nose, nasal congestion, and sneezing symptoms. |
1mg | 113-92-8 | 28 |
| Atificial Cow-bezoar |
It has antipyretic and sedative effects
More
It has antipyretic and sedative effects |
10mg | 1002-00-2 | 2 |